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Edited by Lukas HuberAbstract Tangeretin is a methoxyﬂavone from citrus fruits,
which inhibits growth of human mammary cancer cells and cytol-
ysis by natural killer cells. Attempting to unravel the ﬂavonoids
action mechanism, we found that it inhibited extracellular-
signal-regulated kinases 1/2 (ERK1/2) phosphorylation in a
dose- and time-dependent way. In human T47D mammary can-
cer cells this inhibition was optimally observed after priming with
estradiol. The spectrum of the intracellular signalling kinase
inhibition was narrow and comparison of structural congeners
showed that inhibition of ERK phosphorylation was not unique
for tangeretin. Our data add tangeretin to the list of small kinase
inhibitors with a restricted intracellular inhibition proﬁle.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tangeretin (4 0,5,6,7,8-pentamethoxyﬂavone), a natural com-
pound from citrus fruits, was found to inhibit a number of cell
activities such as growth of mammary cancer cells in vitro [1]
and cytolysis by natural killer (NK) cells in vivo [2]. For both
activities a pivotal role of the mitogen-activated protein kinase
(MAPK)/extracellular-signal-regulated kinase (ERK) pathway
has been reported [3,4]. A variety of peptide growth factors
and steroid hormones are able to activate ERK via upstream
activation of cytoplasmic kinases, including Ras, Src, Raf,
and MAPK kinase (MKK) [5]. The synthetic methoxyﬂavone
PD98059 was identiﬁed as an inhibitor of MKK [6] and hence
of MAPK-driven cell proliferation and NK-cell activity [7]. In-
spired by its structure similarity with PD 98059 and its ability
to suppress cell proliferation and NK-activity as well, we inves-
tigated the eﬀect of tangeretin on the MAPK signalling cas-
cade. The model we used consisted of human T47D breast
cancer cells stimulated with estradiol [8] and treated with tan-*Corresponding author. Fax: +32 9 240 4991.
E-mail address: brackemarc@hotmail.com (M.E. Bracke).
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tion levels of ERK after estradiol treatment, and this
activation, mediated by plasma membrane-bound estrogen
receptors, involves transactivation of ErbB tyrosine kinase
receptors [9]. The dual tyrosine/threonine phosphorylation sta-
tus of ERK was selected as an activation marker for this sig-
nalling pathway.2. Materials and methods
2.1. Cell culture
T47D cells are derived from a pleural eﬀusion of a human mammary
ductal carcinoma. Cells were grown in Dulbeccos modiﬁed Eagles
medium (DMEM) (Invitrogen, Merelbeke, Belgium), supplemented
with 100 IU/ml penicillin, 100 lg/ml streptomycin, 2.5 lg/ml ampho-
tericin B, and 10% heat-inactivated fetal bovine serum (FBS) (Greiner
Bio-one, Wemmel, Belgium) at 37 C in an atmosphere of 10% CO2 in
air.
2.2. Chemicals and antibodies
Tangeretin was kindly provided by Dr. Bill Widmer (Department of
Citrus, Winter Haven, FL), and dissolved in ethanol as a stock solu-
tion of 102 M. 17-b-Estradiol (E2) was from Sigma (St. Louis, MO,
USA), PD 98059 from Calbiochem (La Jolla, CA, USA), and recom-
binant heregulin-b1 (rHRG-b1) from R&D Systems (Abingdon, UK).
The primary antibody for Western blotting was a rabbit polyclonal
anti-phospho-p42/44 MAPK (Thr202/Tyr204) from Cell Signalling
Technology (Beverly, MA, USA). The secondary anti-rabbit antibody
was from Amersham Pharmacia Biotech (Amsterdam, The Nether-
lands). The monoclonal mouse-anti-Syk antibody (clone 4D10) was
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA), while
the polyclonal rabbit-anti-Src CST.1 antibody was kindly provided
by Dr. S. Roche (CNRS FRE2593, Montpellier, France). RU 58668
from Roussel Uclaf (Romainville, France), 4-hydroxytamoxifen (4-
OH-TAM) from Zeneca Pharmaceuticals (Macclesﬁeld, UK) and
[3H]estradiol (±95 Ci/mmol) from Amersham Pharmacia Biotech were
used for estrogen receptor a-mediated luciferase induction and ligand
binding assays.
2.3. Western blotting
All lysates were made from cells at approximately 70% conﬂuency.
For phosphorylation experiments, cells were washed three times with
phosphate-buﬀered saline (PBS), serum-starved overnight, washed
again three times with PBS and treated in serum-free medium. Before
making lysates, the cells were washed again three times with PBS. Cells
were lysed with PBS containing 1% Triton X-100, 1% Nonidet P-40
and the following protease inhibitors: aprotinin (10 lg/ml), leupeptin
(10 lg/ml), phenylmethylsulfonyl ﬂuoride (1.72 mM), NaF (100 M),blished by Elsevier B.V. All rights reserved.
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for 5 min, the samples were sonicated for 15 s. After clearing the ly-
sates by centrifugation at 14000 rpm for 10 min, protein concentration
was determined using the Rc Dc Protein Assay (Bio-Rad, Hercules,
CA, USA) and samples were prepared in such a way that equal
amounts of protein were loaded.
Sample buﬀer [10] with 5% 2-mercaptoethanol and 0.012% bromo-
phenol blue was added, followed by boiling for 5 min and separation
of proteins by gel electrophoresis on a 10% polyacrylamide gel and
transfer onto a nitrocellulose membrane (Amersham Pharmacia Bio-
tech). Quenching and immunostaining of the blots was done in 4% bo-
vine serum albumin in PBS containing 0.2% Tween-20. The
membranes were quenched for 1 h, incubated with primary antibody
for 1 h, washed four times for 10 min, incubated with horseradish per-
oxidase-conjugated secondary antibody for 45 min, and washed six
times for 10 min. Detection was done using Enhanced Chemilumines-
cence reagent (Amersham Pharmacia Biotech) as a substrate. Tubulin
and total p42/p44 immunostaining was used as a loading control, and
variations were less than 5%. After scanning the autoradiogram, bands
quantiﬁcation (the sum of p42 and p44) was performed using the
Quantity One software (Bio-Rad). Experimental results were con-
ﬁrmed by obtaining concordant data from experiments performed at
least in duplo.
2.4. Phosphorylation status analysis of cytoplasmic signalling proteins
Kinetworks technology (Kinexus, Vancouver BC, Canada) permits
the quantitative detection of the phosphorylation status of cytoplasmic
proteins. The Kinetworks KPSS 1.3 Phosphoprotein Screen was per-
formed as described by Pelech et al. [11] (http://www.kinexus.ca). The
screen required 350 lg of protein, and for some kinases results ob-
tained with diﬀerent antibodies are presented.
For the measurement in vitro of Syk and Src tyrosine kinases, Sim-
ian Cos1 cells were transiently transfected with the pCAF1-Syk [12] or
the pSG5-Src cDNA (kindly provided by Dr. S. Roche) using the
SuperFect reagent (Qiagen Inc, Venlo, The Netherlands). Two days
after transfection, cells were lysed and cleared lysates were used for
immunoprecipitation with protein A-agarose beads linked to antibod-
ies against Syk or Src for 3 h at 4 C under constant rotation. Then the
beads were washed in lysis buﬀer and used for Western blot or auto-
phosphorylation testing. For in vitro kinase assays, the beads were
re-suspended in 50 lL reaction buﬀer (10 mM Tris–HCl, pH 8,
10 mM MgCl2, and 10 mM MnCl2). Serial dilutions from a 10
2 M
tangeretin stock solution or piceatannol, a speciﬁc inhibitor of Syk ki-
nase activity (Calbiochem), were made in reaction buﬀer and added to
the beads together with 10 lCi [c-32P] ATP (4500 Ci/mmol, ICN Bio-
medicals) and agitated for 20 min at room temperature. After washing
in reaction buﬀer, beads were boiled in Laemmli sample buﬀer, loaded
on 10% SDS–PAGE gels, dried, exposed and autophosphorylated Syk
or Src kinase levels were detected and quantiﬁed using phosphor-image
analysis (Molecular Dynamics, Sunnyvale, CA).
2.5. Assay for growth of T47D cells in vitro
T47D cells were seeded in microtiter plates at an initial density of
1.5 · 104 cells in 200-ll culture medium. After an incubation period
of 4 days, the amount of cell protein in each well was estimated with
the sulforhodamine B assay [13].
2.6. Luciferase induction assay
MVLN cells are human MCF-7 mammary carcinoma cells, stably
transfected with the pVit-tk-LUC reporter plasmid. These cells allow
quantiﬁcation of the transcriptional activity from estrogen receptor
a-mediated estrogen responsive elements (ERE), in accordance with
the luciferase induction assay by Pons et al. [14]. They were cultured
in 35 mm diameter plastic petri dishes (80000 cells/dish) in DMEM
containing 10% dextran coated charcoal-treated FBS for 3–4 days.
250 ll of 5-fold diluted lysis solution (Promega E153A, Promega,
Madison, WI, USA) was then added to the dishes and maintained
under mild agitation for 20 min to extract luciferase. Lysed cells
were subsequently detached with a scraper and centrifuged for 5 s
at 10000 · g to clarify the extracts. Finally, 20 ll of extracts was
mixed at room temperature with 100 ll of a luciferase reactant med-
ium (Promega E151A/E152A) prepared in accordance with the man-
ufacturers protocol and induced light was measured with a
luminometer.2.7. Statistics
Statistical evaluation of the data was performed with the Students t
test.3. Results
3.1. Dose- and time-dependent eﬀect of tangeretin on the
phosphorylation status of ERK
Western blots were performed to determine whether tangere-
tin could inhibit the E2-induced ERK phosphorylation. T47D
cells were treated with 109 M E2 for 20 min, in the absence or
presence of varying concentrations of tangeretin (107 to
104 M), and assayed for ERK phosphorylation by immuno-
staining with an anti-phospho-MAPK antibody that detects
the dual phosphorylation state (Thr202/Tyr204) of ERK 1/2
(p42 and p44). No activation was observed in solvent (ethanol
0.1%) treated cells as compared to untreated cells, but addition
of E2 induced the phosphorylation of ERK 1/2. Tangeretin
was able to inhibit this E2-induced phosphorylation in a
dose-dependent manner (Fig. 1A).
To determine the kinetics, T47D cells were treated with E2
(109 M) and tangeretin (104 M), and cell lysates were
prepared after various incubation periods (Fig. 1B). ERK
phosphorylation inhibition by tangeretin was evident after
10–30 min.
Since E2 can stimulate the MAPK pathway via ErbB recep-
tors, direct stimulation by rHRG-b1, a ligand of ErbB3 and
ErbB4 [15], was applied as an alternative method to phosphor-
ylate ERK [16]. To conﬁrm the responsiveness of T47D cells to
rHRG-b1, diﬀerent concentrations (0.1–10 ng/ml) were ini-
tially tested and 1 ng/ml for 10 min proved to be an optimal
stimulus. Tangeretin eﬀectively reduced this rHRG-b1 stimu-
lated ERK phosphorylation to 24% at a concentration of
104 M (Fig. 1C).3.2. Eﬀect of tangeretin on growth T47D mammary cancer cells
Tangeretin inhibited the growth of estradiol-stimulated hu-
man T47D cells in the sulforhodamine B assay. The eﬀect
was dose-dependent and could be demonstrated at concentra-
tions from 104 down to 107 M (Fig. 2).3.3. Phosphorylation screening of other signalling molecules
To further investigate the speciﬁcity of the kinase inhibition
by tangeretin, a screening of the phosphorylation status of dif-
ferent cytoplasmic proteins (KPSS 1.3, Kinexus) was per-
formed. Three samples pretreated with 109 M E2 for 20 min
were analysed: one was solvent-treated, a second one was trea-
ted with 104 M tangeretin and the third one with
2.5 · 105 M PD98059 (Table 1). The results showed that tan-
geretin is indeed able to inhibit phophorylation of ERK 1/2
and of MAPK kinases. In contrast to PD98059, tangeretin is
also able to inhibit phosphorylation of other proteins like
adducin a and c, protein kinase Cd, signal transducer and acti-
vator of transcription (STAT) 1 and 3, and stress-activated
protein kinase (JNK). The phosphorylation of other proteins
such as JUN, protein kinase Ba (Akt1), and retinoblastoma
1, however, were increased. Overall the spectrum of inhibition
by tangeretin diﬀered from the one by PD98059.
Quercetin and epigallocatechin-3-gallate were recently
found to down regulate the activity of the Syk kinase and
Fig. 1. Eﬀect of tangeretin on ERK1/2 phosphorylation. T47D cells
were pretreated with estradiol (A and B) or with heregulin (C), and
treated with tangeretin or with solvent. In these typical experiments
shown, tangeretin inhibited ERK1/2 phosphorylation in a dose- (A
and C) and time- (B) dependent way. Western blot analysis and
immunostaining were done with anti-phospho ERK1/2, and results are
presented as percentages of E2- or heregulin-treated cells. Mean
values + S.D., *, P < 0.01.
Table 1
Eﬀect of 104 M tangeretin and 2.5 · 105 M PD98059 on the
phosphorylation status of diﬀerent cytoplasmic kinases and kinase
substrates
Phosphorylation of Tangeretin %
of solvent
control
PD98059
Adducin a 48.3 122.1
Adducin c 50.3 128.7
cAMP response element binding protein 157.3 151.7
Cyclin-dependent kinase 1 (cdc2) 115.2 43.1
dsRNA dependent protein kinase 154.5 11.6
Extracellular regulated kinase 1 64.9 20.9
Extracellular regulated kinase 2 63.5 14.2
Glycogen synthase kinase 3 a 114.6 74.1
Glycogen synthase kinase 3 a 97.8 19.4
Glycogen synthase kinase 3 b 263.5 146.4
Glycogen synthase kinase 3 b 97.3 22.3
MAP kinase kinase 1/2 75.0 104.7
MAP kinase kinase 6 64.7 83.9
N-Methyl-D-aspartate
glutamate receptor unit 1
90.2 143.1
Oncogene JUN 211.8 105.7
Oncogene Raf 1 86.3 89.3
Oncogene Raf 1 95.6 64.9
Oncogene SRC 72.4 69.7
Oncogene SRC 110.8 86.5
P38 a MAP kinase 104.4 116.6
Protein kinase B a (Akt1) 161.3 87.5
Protein kinase B a (Akt1) 138.3 99.9
Protein kinase C a 127.7 162.3
Protein kinase C a/b 101.9 217.5
Protein kinase C d 73.7 127.3
Protein kinase C e 92.1 91.3
Retinoblastoma 1 127.6 150.3
Retinoblastoma 1 131.5 207.4
S6 kinase p70 56.3 119.6
STAT 1 70.7 99.1
STAT 3 66.6 78.9
Stress-activated protein kinase (JNK) 78.6 84.5
Stress-activated protein kinase (JNK) 64.1 126.8
Fig. 2. Eﬀect of tangeretin on growth of estradiol-stimulated human
T47D cells. The cells were treated with diﬀerent tangeretin concentra-
tion for 4 days, and the amount of cellular protein was assessed with
the sulforhodamine B assay and expressed as optical density units
(OD). Bars indicate mean values + S.D., *, P < 0.01.
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geretin on the Syk and Src kinase activities, their autophos-
phorylation capacity was tested in vitro by incorporation of
[c-32P] ATP in presence of increasing tangeretin concentra-
tions. On Syk and Src kinase autophosphorylation levels
no eﬀect of tangeretin could be observed, yet piceatannol
at 104 M completely abolished Syk autophosphorylation
(data not shown).3.4. Eﬀects of methoxyﬂavone congeners on ERK
phosphorylation
A number of methoxyﬂavones and methoxyisoﬂavones were
tested for their ability to aﬀect ERK phosphorylation in E2-
stimulated T47D cells (Fig. 3A). At 104 M 5,6,7,8,3 0,4 0,5 0-
heptamethoxyﬂavone (349) and 2,7-dimethoxyﬂavone (345)
were more potent than tangeretin (Fig. 3B).
Fig. 3. Structures of methoxyﬂavone/methoxyisoﬂavone congeners of tangeretin (A), and their eﬀect on ERK1/2 phosphorylation in T47D cells (B).
In this typical experiment shown, E2-stimulated (20 min) T47D cells were treated in absence or presence of diﬀerent methoxyﬂavones or methoxy-
isoﬂavones at a concentration of 104 M. Western Blot analysis and immunostaining were done with anti-phospho ERK1/2. Results are presented as
percentages of phosphorylation in tangeretin-treated cells.
Fig. 4. Luciferase induced activity (%) of tangeretin (105 to 109 M)
in MVLN cells.
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transcription activity
Because it has been reported that some ﬂavonoids can
bind to the estrogen receptor, the eﬀect of tangeretin on
ERE-dependent transcription activity was measured. Treat-
ment of MVLN cells for 24 h was done in the presence
of 1010 M E2, 107 M 4-OH-TAM, 107 M RU58668,
and diﬀerent concentrations of tangeretin. Increase of
ERE-luciferase activity was observed with E2 (+110%),
while partial (4-OH-TAM) and pure (RU58668) anti-estro-
gens decreased the basal transcriptional activity by 65%
and 55%, respectively. With tangeretin (105 to 109 M)
neither stimulatory nor inhibitory eﬀects on luciferase induc-
tion could be observed (Fig. 4). No aﬃnity neither for the
intracellular estrogen receptor a nor for the membrane
estrogen binding sites could be attributed to tangeretin in
a ligand binding competition assay with [3H] estradiol (data
not shown).4. Discussion
This report adds tangeretin to the list of ﬂavonoids that were
previously described in the literature as kinase inhibitors.
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pp60src by quercetin [17], and of receptor tyrosine kinases by
high-dose genistein [18]. Moreover, several pharmacological
inhibitors of kinases belong to the ﬂavonoid family, and PD
98059, the gold standard inhibitor for MAPK phosphorylation
in vitro, is a synthetic methoxyﬂavone structurally related to
tangeretin. Tangeretin, however, diﬀers from genistein [19]
and PD 98059 [20] in that it is devoid of any estrogenic or
anti-estrogenic activity.
A number of tangeretins eﬀects on cell behaviour can be
matched with inhibition of ERK signalling. This pathway
has shown to be involved in cell proliferation [5], motility
and invasion [21], and natural killer cell activity [4]. Inhibition
of the pathway by tangeretin treatment could explain the ef-
fects observed in several functional assays in vitro [22].
Tangeretin can be considered as a small kinase inhibitor with
a restricted activity spectrum, and some molecules of this class
may become drugs with potential therapeutic applications in
mammary cancer [23,24]. Major interest has resulted from suc-
cessful therapeutic use of a tyrosine kinase inhibitor coined
imatinib (Glivec, Gleevec), which has now received interna-
tional approval as the ﬁrst-line treatment for chronic myeloid
leukemia and gastro-intestinal stromal cell tumors [25]. Imati-
nib shares one important feature with tangeretin in that oral
treatment is the application route of choice to obtain an eﬀect
on (tumor) cell growth in vivo. Oral administration of tangere-
tin to laboratory mice has indeed been shown to exert an eﬀect
on cancer immune surveillance cells and signiﬁcantly aﬀects tu-
mor growth [2]. Furthermore, a safety study with laboratory
mice receiving tangeretin chronically in their drinking water
has shown no eﬀects on several blood parameters, except for
a reduced number of circulating lymphocytes in the blood
[2]. So, considering the eﬀectiveness after oral administration,
the safety in laboratory animals and the restricted kinase inhi-
bition scope, tangeretin is a natural product with potential
applications in medicine.
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